ASH 2019 | CStone’s anti-PD-L1 antibody demonstrates a complete response rate of 31.8% in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma
PR Newswire
November 7, 2019 β 11:02 CST
UNLOCK DATA Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech